Have a personal or library account? Click to login
Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib Cover

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib

Radiology and Oncology
Volume 52 (2018): Issue 2 (June 2018)
By:
Open Access
|Jan 2018

References

  1. Arnold M, Holterhues C, Hollestein LM, Coebergh JWW, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. <em>J Eur Acad Dermatol Venereol JEADV</em> 2014; <bold>28</bold>: 1170-8. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1111/jdv.12236" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/jdv.12236</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  2. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. <em>Eur J Cancer</em> 2016; <bold>63</bold>: 201-17. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ejca.2016.05.005" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejca.2016.05.005</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  3. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <em>N Engl J Med</em> 2014; <bold>371</bold>: 1867-76. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1056/NEJMoa1408868" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJMoa1408868</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  4. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em> 2015; <bold>26</bold>: v126-32. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/annonc/mdv297" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdv297</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  5. Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. <em>J Transl Med</em> 2012; <bold>10</bold>: 85. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1186/1479-5876-10-85" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/1479-5876-10-85</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  6. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? <em>Lancet Oncol</em> 2013; <bold>14</bold>: e60-9. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/S1470-2045(12)70539-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S1470-2045(12)70539-9</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  7. Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL, Dummer R, Goldinger SM. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. <em>Eur J Cancer</em> 2016; <bold>65</bold>: 130-8. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ejca.2016.06.018" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejca.2016.06.018</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  8. Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. <em>Ophthalmology</em> 2017. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ophtha.2017.05.038" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ophtha.2017.05.038</a></pub-id>. [Epub ahead of print]
    Open DOISearch in Google ScholarBack to article
  9. Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. <em>Am J Ophthalmol</em> 2014; <bold>158</bold>: 831-837.e2. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ajo.2014.07.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ajo.2014.07.003</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  10. Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. <em>Ann Oncol</em> 2017; <bold>28</bold>: 1137-44. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/annonc/mdx040" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdx040</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  11. de la Cruz-Merino L, Di Guardo L, Grob J-J, Venosa A, Larkin J, McArthur GA, et al. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. <em>J Transl Med</em> 2017; <bold>15</bold>: 146. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1186/s12967-017-1246-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s12967-017-1246-0</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  12. Alves C, Ribeiro I, Penedones A, Mendes D, Batel Marques F. Risk of ophthalmic adverse effects in patients treated with MEK inhibitors: A systematic review and meta-analysis. <em>Ophthalmic Res</em> 2017; <bold>57</bold>: 60-9. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1159/000446845" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1159/000446845</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  13. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. <em>Ther Adv Med Oncol</em> 2015; <bold>7</bold>: 122-36. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1177/1758834014566428" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/1758834014566428</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  14. Schoenberger SD, Kim SJ. Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma. <em>Case Rep Ophthalmol Med</em> 2013; <bold>2013</bold>: 1-3. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1155/2013/673796" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1155/2013/673796</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  15. Michalarea V, de Miguel Luken MJ, Diamantis N, Garg A, Maubon L, Yap TA, et al. Ocular toxicity with MEK inhibitors in phase I trials: A single centre experience across six clinical trials. <em>J Clin Oncol</em> 2015; <bold>33</bold>: 11090-90. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1200/jco.2015.33.15_suppl.11090" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/jco.2015.33.15_suppl.11090</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  16. van Dijk EHC, van Herpen CML, Marinkovic M, Haanen JBAG, Amundson D, Luyten GPM, et al. Serous retinopathy associated with mitogen-activated protein kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma. <em>Ophthalmology</em> 2015; <bold>122</bold>: 1907-16. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ophtha.2015.05.027" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ophtha.2015.05.027</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  17. Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. <em>JAMA Ophthalmol</em> 2016; <bold>134</bold>: 855-62. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1001/jamaophthalmol.2016.0090" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1001/jamaophthalmol.2016.0090</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  18. Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. <em>Ann Oncol</em> 2016; <bold>27</bold>: 998-1005. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/annonc/mdw100" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdw100</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  19. Jiang Q, Cao C, Lu S, Kivlin R, Wallin B, Chu W, et al. MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. <em>Int J Mol Med</em> 2009; <bold>23</bold>: 771-7.
    Search in Google ScholarBack to article
  20. Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. <em>J Ocul Pharmacol</em> 2009; <bold>25</bold>: 519-30. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1089/jop.2009.0060" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1089/jop.2009.0060</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  21. Runkle EA, Antonetti DA. The blood-retinal barrier: Structure and functional significance. In: Nag S, editor. <em>Blood-Brain Neural Barriers</em>, vol. 686, Totowa, NJ: Humana Press; 2011. p. 133-48.
    Search in Google ScholarBack to article
  22. Niro A, Strippoli S, Alessio G, Sborgia L, Recchimurzo N, Guida M. Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase inhibitors: a case series. <em>Am J Ophthalmol</em> 2015; <bold>160</bold>: 959-67. e1. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ajo.2015.07.035" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ajo.2015.07.035</a></pub-id>
    Open DOISearch in Google ScholarBack to article
  23. Guedj M, Quéant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. <em>JAMA Ophthalmol</em> 2014; <bold>132</bold>: 1421-5. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1001/jamaophthalmol.2014.3024" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1001/jamaophthalmol.2014.3024</a></pub-id>
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/raon-2018-0002 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 213 - 219
Submitted on: Oct 4, 2017
Accepted on: Nov 20, 2017
Published on: Jan 24, 2018
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
metastatic malignant melanoma,
eye,
MEKAR,
MEK inhibitor
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2018 Ana Ursula Gavric, Janja Ocvirk, Polona Jaki Mekjavic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 52 (2018): Issue 2 (June 2018)Next article